Perampanel (PER), a novel 3rd-generation antiseizure drug that modulates altered post-synaptic glutamatergic storming by selectively inhibiting AMPA receptors, is recently approved to treat intractable forms of seizures. However, to date, presumably consequences of long-term PER therapy on the comorbid deleterious psychiatric disturbances and its correlation with neuroinflammatory parameters are not fully investigated in chronic models of epilepsy. Therefore, we investigated the real-time effect of PER on brain electroencephalographic (EEG) activity, behavioral alterations, redox balance, and relative mRNA expression in pentylenetetrazole (PTZ) induced kindling. Male BALB/c mice were pretreated with PER (0.125, 0.25, and 0.5 mg/kg) for 3 we...
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that pe...
Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Instit...
Perampanel is a non-competitive AMPA receptor antagonist that is under development as an anti-epilep...
Objective: Perampanel (PER), a selective non-competitive a-amino-3-hydroxy-5methyl- 4-isoxazolepropi...
Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily compose b...
Treatment options for Dravet syndrome are limited. The aim of this study was to evaluate the antiepi...
The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are the major mediato...
To elucidate the pharmacological properties of perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihy...
Energy depletion caused by ischemic brain insults may result in persistent neuronal depolarization a...
Perampanel is a new chemical entity recently approved in the United States (US) and European Union (...
Epilepsy is a serious brain disorder with diverse seizure types and epileptic syndromes. AMPA recept...
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the postsynaptic membrane a...
Persistent activation of ionotropic glutamatergic receptors contributes to seizure sustenance and ne...
AbstractIntroductionIn refractory status epilepticus (SE), because of subcellular maladaptive change...
Andreas Schulze-Bonhage, Mandy Hintz Epilepsy Center, University Medical Center Freiburg, Freiburg,...
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that pe...
Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Instit...
Perampanel is a non-competitive AMPA receptor antagonist that is under development as an anti-epilep...
Objective: Perampanel (PER), a selective non-competitive a-amino-3-hydroxy-5methyl- 4-isoxazolepropi...
Glutamate is the brain's main excitatory neurotransmitter. Glutamatergic neurons primarily compose b...
Treatment options for Dravet syndrome are limited. The aim of this study was to evaluate the antiepi...
The alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors are the major mediato...
To elucidate the pharmacological properties of perampanel [2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihy...
Energy depletion caused by ischemic brain insults may result in persistent neuronal depolarization a...
Perampanel is a new chemical entity recently approved in the United States (US) and European Union (...
Epilepsy is a serious brain disorder with diverse seizure types and epileptic syndromes. AMPA recept...
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the postsynaptic membrane a...
Persistent activation of ionotropic glutamatergic receptors contributes to seizure sustenance and ne...
AbstractIntroductionIn refractory status epilepticus (SE), because of subcellular maladaptive change...
Andreas Schulze-Bonhage, Mandy Hintz Epilepsy Center, University Medical Center Freiburg, Freiburg,...
Glioma-associated epilepsy is associated with excessive glutamate signaling. We hypothesized that pe...
Sylvain Rheims,1,2 Philippe Ryvlin1,21Department of Functional Neurology and Epileptology and Instit...
Perampanel is a non-competitive AMPA receptor antagonist that is under development as an anti-epilep...